172 related articles for article (PubMed ID: 15646073)
1. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Gianotti N; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Castagna A
New Microbiol; 2004 Apr; 27(2 Suppl 1):111-7. PubMed ID: 15646073
[TBL] [Abstract][Full Text] [Related]
2. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.
Gianotti N; Galli L; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Lazzarin A; Clementi M; Castagna A
New Microbiol; 2005 Oct; 28(4):319-26. PubMed ID: 16386016
[TBL] [Abstract][Full Text] [Related]
3. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
4. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Jakobsen MR; Tolstrup M; Bertelsen L; Laursen A; Obel N; Ostergaard L; Mohey R
J Clin Virol; 2007 Jul; 39(3):215-21. PubMed ID: 17540617
[TBL] [Abstract][Full Text] [Related]
6. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
7. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
Palmer S; Boltz V; Maldarelli F; Kearney M; Halvas EK; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Mellors JW; Coffin JM
AIDS; 2006 Mar; 20(5):701-10. PubMed ID: 16514300
[TBL] [Abstract][Full Text] [Related]
8. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
9. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
Cozzi-Lepri A; Paredes ; Phillips AN; Clotet B; Kjaer J; Von Wyl V; Kronborg G; Castagna A; Bogner JR; Lundgren JD;
HIV Med; 2012 Jan; 13(1):62-72. PubMed ID: 21848790
[TBL] [Abstract][Full Text] [Related]
10. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
[TBL] [Abstract][Full Text] [Related]
11. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
12. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
13. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
14. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
15. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
16. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
17. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
18. NNRTIs: a neglected class.
Cadman J
GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
[TBL] [Abstract][Full Text] [Related]
20. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]